Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Ultimovacs As Stock

Price
Target price
€0.63

€0.63

11.500%
0.065
11.500%
-
 
30.04.24 / Frankfurt WKN: A2PKSD / Name: Ultimovacs As / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Ultimovacs As in the next few years
Wizard

Ultimovacs As Stock

Ultimovacs As dominated the market today, gaining €0.065 (11.500%).
What does Ultimovacs As do?

Pros and Cons of Ultimovacs As in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-10

In looking at the financials of the company Ultimovacs As, a general impression emerges of an organization with strong liquidity and a solid balance sheet, despite no revenue generation. However, they are operating with significant net losses annually, which could raise some concerns.

Strong Liquidity: Ultimovacs As has consistently demonstrated a high level of cash and cash equivalents in its financial statements, which allows the company to meet its obligations and invest in research and development activities without relying on external financing.

Healthy Working Capital: The company has maintained a positive net working capital in the past few years, which indicates operational efficiency and a capacity to cover short-term liabilities with short-term assets.

Show more
Register To Post